Navigation Links
New oral drug candidate for African sleeping sickness
Date:12/6/2012

extensive compound mining efforts pursued by DNDi within the nitroimidazole project initiated in 2005 to explore new and old nitroimidazole drug leads. The objective is to progress fexinidazole through this pivotal Phase II/III study in order to register the drug as a new treatment for stage 2 sleeping sickness caused by the parasite Trypanosoma brucei (T.b.) gambiense, as well as for stage 1 sleeping sickness and sleeping sickness caused by T.b. rhodesiense.

If ultimately successful, fexinidazole would be the first oral treatment to be used for both stage 1 and stage 2 sleeping sickness, thereby replacing the complicated diagnosis and treatment paradigm, which includes systematic lumbar punctures of every diagnosed patient to determine the stage of the disease before deciding which treatment to administer.

'This new chemical entity gives us hope of a drastically simplified way to care for our patients', said Dr Wilfried Mutombo, National Human African Trypanosomiasis Control Programme , DRC, Investigator and Coordinator of the fexinidazole trial. 'In addition, the investments made into renovating the laboratories and hospital wards, training personnel, and introducing adapted technologies that allow us to report in real time on each patient, has elevated an entire group of dedicated professionals to international clinical research standards', he added.

The study was initiated and is conducted by DNDi in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) and the Human African Trypanosomiasis national control programmes of the Democratic Republic of the Congo and Central African Republic, in addition to collaboration with Mdecins Sans Frontires (MSF). The French pharmaceutical company Sanofi and DNDi co-develop the drug: DNDi is responsible for preclinical, clinical, and pharmaceutical development, while Sanofi is responsible for the industrial development, registration, and production of the drug at its man
'/>"/>

Contact: Violaine Dllenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Novel drug candidates offer new route to controlling inflammation
2. Presidential candidates should address childhood obesity and bullying, poll says
3. Parc at Piedmont - East Cobb to Host Candidate Forum for Primary Elections
4. New candidate drug stops cancer cells, regenerates nerve cells
5. BWH researchers discover new vaccine candidate for Pseudomonas aeruginosa
6. No Truth to Candidates Claim That Rape Hinders Pregnancy, Experts Say
7. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
8. Can weight loss help African-American breast cancer survivors?
9. Equal access to care helps close survival gap for young African-American cancer patients
10. Systemic sclerosis complications more severe in African Americans than Caucasians
11. Genetic marker may predict smoking quantity in African Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... The print component of Healthy Aging is ... approximately 160,000 copies and an estimated readership of 420,000. ... social media strategy and across a network of top ... version of the campaign, click here . , ... ladies of CTV’s The Social. Lainey Lui, Melissa ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Atore, Inc, ... company just launched first birthday focused portal on December ... BIRTHDAY MESSAGE” launched in both US and Japan. , ... MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE ... birthday around the world. , Features, Choose from thousands ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... that the scents of peppermint or cinnamon could make the ... for long stretches of time makes the drivers of the ... drivers who participated in the study under the conditions of ... control. The odors were added to the air inside the ...
... having fractures, are often routinely prescribed vitamin D and supplemental// ... light the fact that this may not be true. Calcium ... in the elderly people. ,The study had looked into ... people were mobile before they had a low trauma fracture. ...
... risk factor for multiple sclerosis. New study shows that ... suffering from multiple sclerosis. ,In a research done ... had been able to associate habitual smoking with rapid ... study comprising of 201 cases of multiple sclerosis and ...
... that it is possible to generate insulin from brain stem ... was given to patient suffering from type 1 diabetes mellitus, ... where there is availability of insulin, even there remains a ... such is inability of the patient to synthesize insulin in ...
... journal cancer Research, tobacco smoke have been linked with the ... 2 is a cellular protein that had been related to ... been related to rise in production of two proteins that ... lead to the production of the chemical Cox 2. ...
... that intake of calcium supplements over the years can ... of colon cancer.// ,Calcium supplements can reduce ... in colon. Calcium has chemo protective properties that can ... study was in a trial, which observed 930 patients ...
Cached Medicine News:
(Date:12/19/2014)... , Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. ... agreement with MSN Laboratories Pvt. Ltd. ( Hyderabad, ... to commercialize several new ANDAs.  Under the terms of ... products exclusively to Breckenridge for the U.S. market, and ... label.  Breckenridge and MSN have agreed to develop an ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
... a four channel Platelet Aggregation Profiler with ... assay (Ristocetin cofactor), platelet aggregation and leukocyte ... for the evaluation and confirmation of Heparin ... tests to be run simultaneously and independently. ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Medicine Products: